Form 4: Artiva CEO Sells Shares for Tax, 10b5-1 Plan
Insider Transaction Report
Artiva Biotherapeutics' President and CEO, Fred Aslan, reported sales of common stock totaling 12,722 shares, primarily for tax obligations and under a pre-arranged 10b5-1 trading plan.
Summary
- Fred Aslan, President and CEO, and a Director of Artiva Biotherapeutics, Inc. (ARTV), reported two transactions involving common stock.
- On November 15, 2025, 6,347 shares were disposed of at $3.25 per share to cover income tax obligations associated with restricted stock unit vesting.
- On November 17, 2025, an additional 6,375 shares were sold at a weighted average price of $3.376 per share (ranging from $3.19 to $3.53).
- This latter sale was executed under a Rule 10b5-1 trading plan adopted by Mr. Aslan on July 23, 2024.
- Following these transactions, Mr. Aslan directly beneficially owns 343,999 shares of Artiva Biotherapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral. The transactions are routine insider sales for tax purposes and under a pre-arranged 10b5-1 plan, which are generally not indicative of positive or negative sentiment regarding the company's future prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The sale of shares by a key executive slightly reduces their direct ownership stake, but the nature of the sales (tax withholding, 10b5-1 plan) suggests these are routine and not based on new material information, thus likely having minimal direct impact on shareholder perception.
Key Dates
| Date | Description |
|---|---|
| 07/23/2024 | Date Rule 10b5-1 Plan was adopted by Fred Aslan. |
| 11/15/2025 | Date of disposition of 6,347 shares for tax obligations related to RSU vesting. |
| 11/17/2025 | Date of disposition of 6,375 shares under a Rule 10b5-1 Plan. |
| 11/17/2025 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThe filing is a routine Form 4 detailing insider stock sales for tax obligations and under a pre-arranged 10b5-1 plan. These transactions are not indicative of any fundamental change in the company's prospects or a signal for investors to buy or sell. Therefore, a "hold" recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.
Keywords
Artiva Biotherapeutics, ARTV, Fred Aslan, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Restricted Stock Units, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.